CAQK
A tetrapeptide studied in research on targeted delivery to injured brain and spinal-cord tissue.
CAQK is a short cyclic or linear peptide of four amino acids (Cys-Ala-Gln-Lys), discovered through phage-display technology in research on targeted drug delivery for central nervous system injuries. It has a unique, highly selective ability to recognise and bind components of the altered extracellular matrix only in injured brain and spinal-cord tissue — specifically the chondroitin sulfate proteoglycan complexes (CSPGs) secreted by damaged glial tissue. CAQK works as a smart molecular delivery vehicle (homing / targeting peptide): it is linked to nano-carriers, anti-inflammatory drugs or building peptides to carry them directly across the damaged blood–brain barrier to the precise centre of the injury, limiting neuronal death and reducing glial scarring without affecting healthy tissue.
The targeted biological vehicle that carries treatment straight to the focus of brain injuries
If the biggest obstacle in treating head trauma and spinal-cord damage is getting drugs precisely to the injury site without wasting them in healthy tissue, CAQK is the smartest molecular navigation system in regenerative neurology.
Classification: Cellular homing and targeting peptides, treatment of brain and spinal-cord injury, and nanoparticle delivery (Homing Peptides / Brain Injury Targeting).
Structurally, it consists of a very precise sequence of four amino acids — cysteine, alanine, glutamine and lysine. This arrangement gives it a chemical affinity that binds exclusively to the distorted proteins and sugars secreted by damaged neural tissue at the moment of trauma.
Picture a concussion or traumatic spinal-cord injury: the injured nerve cells send out a chemical distress call and secrete a network of damaged proteins around themselves, yet most drugs injected into the blood cannot concentrate in that specific area.
How it works
When CAQK is injected into the circulation, it completely ignores healthy brain regions and heads like an arrow to the site of acute neural injury, where it binds strongly to CSPGs in the damaged matrix. Used as a linking and guidance tool for biological carriers, it pulls neuroprotective drugs, anti-inflammatories or growth factors directly into the heart of the damaged tissue. The result is precisely targeted reduction of brain swelling and inflammation at the injured site, limited spread of damage to neighbouring cells and inhibition of the glial scars that block nerve regeneration.
In research settings, it is studied as a revolutionary platform for traumatic brain injury, spinal-cord damage and ischaemic stroke, to deliver gene therapies and nanoparticles to their specific target.
Rescuing nerve cells after trauma needs not only powerful therapeutic molecules but a biological guide that delivers them with great precision to the danger zone.
The smart navigation system for repairing brain damage and spinal-cord injury. CAQK is an advanced innovation in targeted-delivery research within the central nervous system. It belongs to the class of homing peptides that target injured neural tissue. Its four amino acids are designed to recognise precisely the distress signals and specific proteins secreted by damaged brain cells after trauma, acting as a biological transport vehicle that directs drugs and healing factors straight into the heart of the injury without touching healthy tissue. Its mechanism penetrates sites of neural damage and concentrates therapeutic substances there — easing swelling and brain inflammation, preventing the spread of nerve-fibre damage and limiting scars that hinder healing. Leading neuroscientists study it as the newest strategy for treating concussion and spinal-cord injuries with exceptional precision and effectiveness — because therapeutic success begins by placing the right medicine exactly where the damage is.
